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Introduction: This study aimed to evaluate the feasibility and beneﬁt of a structured exercise intervention
in people with Huntington’s Disease (HD).
Methods: This study was conducted at 6 sites, and participants were randomized into either exercise or
control (usual care) groups, and were assessed at baseline, 13 and 26 weeks. The intervention was a 12
week, three times per week progressive exercise program, including aerobic (stationary cycling) and
upper and lower body strengthening exercise with tapered 1:1 support for 20 of 36 sessions.
Results: 314 adults were assessed for eligibility: 248 did not meet inclusion criteria, 34 declined, and 32
were recruited and randomized. Three individuals in the intervention group were withdrawn within the
ﬁrst month due to concomitant medical conditions, resulting in 14 participants in intervention and 15 in
control groups. There were two AEs in the intervention group, both related to previous medical condi-
tions, and there were two SAEs, both in the control group. The intervention group had better ﬁtness
(predicted VO2 max difference: 492.3 ml min1, 95% CI: [97.1, 887.6]), lower UHDRS mMS (difference 2.9
points, 95% [5.42, 0.32]) and lower weight at Week 13 (difference 2.25 kg, 95% CI: [4.47, 0.03]).
Conclusion: This study demonstrates that a short-term exercise intervention is safe and feasible. In-
dividuals with HD may beneﬁt from structured exercise, and intensity, monitoring and support may be
key factors in optimizing response. Larger scale trials are now required to fully elucidate the extended
clinical potential of exercise in HD.
Trial registration: Current Controlled Trials ISRCTN11392629.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).ences, Cardiff University, Ty
).
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Ltd. This is an open access article u1. Introduction
Aerobic and multi-modal exercise interventions are well known
for their effect on cardiorespiratory ﬁtness, muscle strength,
depression and cognition [1], and in recent years, beneﬁts of ex-
ercise and physical activity have been studied in Huntingtonnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Furthermore, longer term multidisciplinary rehabilitation has
resulted in improvements in gait, balance and quality of life [7,8],
and evidence suggests it may impact cognitive function [9]. How-
ever, clear beneﬁt as a result of participating in a shorter-term
exercise program incorporating targeted aerobic and strength
training has yet to be established.
A variety of challenges are associated with exercise in-
terventions in people with complex neurodegenerative diseases
such as HD, not least that associated with cognitive andmotor signs
of the disease. In a recent study, a home-based exercise interven-
tion was well received by participants; however, carer support was
needed to facilitate and at times supervise the exercise program [3].
Results from a gym-based program suggest that while it was safe
and feasible for individuals to engage in an aerobic exercise pro-
gram, overall intensity of the intervention may not have been
sufﬁcient to achieve a training effect [4]. Information obtained from
process interviews also suggested that some participants found the
gym environment intimidating. In order to develop a successful
exercise intervention, acceptable to a wide number of people with
HD, it is critical to include personal preferences of exercise envi-
ronment to facilitate uptake and adherence.
Complex physical and cognitive impairments in HD can impact
on a person’s ability to initiate and adhere to an exercise program
[10]. Ensuring sufﬁcient intensity of exercise to achieve an aerobic
effect is a further challenge. Thus a supported, structured, mixed
delivery approach may facilitate awider range of people with HD to
engage in exercise. Here we present results from a randomized
controlled trial of an exercise program delivered with tapered
professional support. This study was designed to evaluate a more
intensive, progressive exercise program than has been previously
studied in this population. The speciﬁc objectives were to identify
whether a 3-month, three times per week exercise program in
people with HD was: 1) safe, 2) feasible in terms of adherence and
retention, 3) improved physical ﬁtness, and 4) improved func-
tioning in other domains, such as motor and cognitive function.
2. Methods
2.1. Study design
This was a single-blind, multi-site randomized controlled trial of
an exercise intervention compared to usual care. Assessments were
taken at baseline and 13weeks. Follow up phone calls weremade at
26 weeks to assess health status and physical activity. Fig. 1 illus-
trates the CONSORT ﬂowchart.
2.2. Site and participant selection
The trial was carried out at six HD specialist clinics that were
ENROLL-HD/Registry (13/WA/0192), sites: Cardiff, UK; Birmingham,
UK; Oxford, UK; Leiden, Netherlands; Münster, Germany; and Oslo,
Norway. ENROLL-HD is a worldwide observational study of Hun-
tington’s disease families, and provides a platform for clinical
studies to facilitate recruitment into clinical trials. Exclusion and
inclusion criteria are shown in Table 1.
2.3. Recruitment
The recruitment period was March 2014 to January 2015 with a
target of 42 participants. Patients receiving routine HD clinical care
or attending an ENROLL-HD assessment were given trial informa-
tion. An invitation letter and information sheet was sent to
ENROLL-HD patients who were potentially eligible but not due to
visit clinic imminently; those participants subsequently attendedan ENROLL-HD appointment and were reviewed by the site Prin-
cipal Investigator (PI). All participants gave written informed con-
sent. Site PIs were responsible for ensuring that each participant
was capable of giving informed consent.2.4. Screening
Each site kept a screening log, which recorded details of number
of people approached about the trial and eligibility.2.5. Blinding
Data collection was conducted by blinded assessors. Site co-
ordinators requested participants not disclose their allocation to
the assessors. Incidents of unblinding were recorded.2.6. Randomization
The trial coordinator performed randomization centrally for
each participant during their baseline assessment; group assign-
ment was conveyed to respective site coordinators by phone, who
then informed the participant privately following completion of
baseline assessment. Randomization ratio of intervention to control
arm was 1:1. A minimization procedure [11] was used to achieve
balance between groups; variables used for minimizationwere site,
age, gender, and Uniﬁed Huntington’s Disease Rating Scale Total
Motor Score (UHDRS TMS) [12].2.7. Intervention
The intervention group participated in a 12-week exercise
program; control group was asked to continue as usual. The
intervention consisted of a 50-min structured aerobic, strength-
ening and stretching routine, and could take place either in a
hospital-based gym, or participant’s homewith exercise equipment
provided by the researchers. Physical therapists or certiﬁed ﬁtness
professionals (referred to as trainers henceforth) delivered the
intervention, and monitored prescribed exercise dose, progression
and safety. Trainers provided support in a tapered process for 20/36
sessions: for weeks 1e2, trainers supervised 3/3 sessions; for
weeks 3e6, 2/3 sessions were supervised with 1 independent
session; for weeks 7e12, 1/3 sessions were supervised.
Sessions followed a set program including a 5-minwarm up and
up to 25min on the bike within an aerobic zone. Intensity of warm-
up was at 50e60% age predicted maximum heart rate (APMHR,
deﬁned as 220-age) and aerobic zone was in a range of 65e85%
APMHR. Trainers progressed participants by initially working to
achieve the full 30 min of training time and then increasing in-
tensity within the training zone. During the last 3 min, intensity
was tapered to the lower end of training zone. Following the aer-
obic exercise was 10e15 min of strengthening, consisting of lower
extremity and core activities, ending with 5 min of stretching (see
Appendix 1).
In supported sessions, trainer’s recorded detailed resistance,
speed of pedalling, heart rate (HR) and perceived exertion at 5-min
intervals for aerobic training on the bike, and sets, repetitions and
weights for strengthening exercises. Participants were provided
with exercise diaries for independent sessions.
Participants assigned to the control group were instructed to
continue as normal. Following completion of the study, control
group participants were offered gymmembership for 12 weeks or a
home exercise bike, including two trainer visits.
Fig. 1. ExeRT-HD CONSORT Flow chart.
Table 1
Participant inclusion/exclusion criteria.
Inclusion criteria Exclusion criteria
1) genetically conﬁrmed diagnosis of HD
2) above the age of 18 years
3) stable medication regime for four weeks prior to initiation of trial, and anticipated
to be able to maintain a stable regime for the course of trial
1) any physical or psychiatric condition that would prohibit the participant from
completing the intervention or the full battery of assessments
2) inability to independently use the exercise bike
3) unable to understand or communicate in spoken English (UK sites only)
4) currently involved in any intervention trial or within four weeks of completing an
intervention trial
5) current, regular participation in a structured exercise program ﬁve times per
week or more
HD ¼ Huntington’s disease.
L. Quinn et al. / Parkinsonism and Related Disorders 31 (2016) 46e52482.8. Safety for exercise
Participants were screened for risk factors for exercise [13], and
completed the Physical Activity Readiness Questionnaire (PAR-Q)
[14] and a resting electrocardiogram (ECG) to ensure safety toinitiate an exercise program. If abnormal results were found par-
ticipants were referred to their primary physician or cardiologist,
depending on the site, for further evaluation before being allowed
to enrol in the trial.
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We collected demographic data of age and gender, and height
and weight were measured. Medication was recorded at baseline
and any medication changes at Week 13 were noted. Medications
were coded according to classiﬁcation and indication.
2.10. Outcomes
Outcomes of safety, feasibility, and effectiveness were assessed.
Safety was assessed by review of weekly health and falls diaries,
which included information on falls history, medication changes,
healthcare service use and hospital admissions (classiﬁed as
adverse events (AEs)). Diaries were given to all participants at
baseline assessment and were returned at Week 13.
The primary feasibility objective was evaluation of recruitment,
retention and adherence rates. Recruitment was assessed using site
recruitment logs. Retention rate was measured as percentage of
individuals who completed the intervention. Adherence rates were
deﬁned as percentage of intervention sessions completed. Suc-
cessful intervention adherence was pre-deﬁned as at least 75% of
supervised sessions (15/20 sessions), and 75% of unsupervised
sessions (12/16 sessions), completed with average HR over session
duration within the aerobic zone.2
The primary efﬁcacy outcome in terms of short-term beneﬁt
was physical ﬁtness measured using a predicted VO2 max equation
[15], by stepwise incremental exercise test (Appendix 2).3 Expired
air and capillary blood samples4 were collected at two sites during
the exercise test. Expired air measures provided information about
gas exchange during exercise, which was used to validate the
predicted test equation [15].
Secondary outcome measures included measures of motor
function, ambulation and cognition (Appendix 3).
2.11. Training and site monitoring
We conducted a one-day training for assessors and trainers,
which was videotaped for future viewing. Additional on-site
training was conducted.5 Assessors conducting UHDRS TMS and
mMS were required to have Motor Rating Certiﬁcation [16].
Monitoring occurred face-to-face or via remote video on at least
two occasions per site. Trainers maintained detailed session notes
for each training session, which were reviewed by the PI during the
trial to assure intervention ﬁdelity.
2.12. Sample size
We planned to recruit 42 participants to allow us to estimate
any feasibility proportion to within plus or minus 15.1% points.
While demonstrating efﬁcacy was not an aim of the study, with 34
participants in total (17 per group, 20% attrition) we could detect a
standardised difference of 1.0 at the ﬁnalmeasurement point with a
power of 80%.2 Acceptability of the intervention and further analysis of intervention ﬁdelity
and progression was assessed via structured questionnaires with research partici-
pants and trainers on completion of the intervention and will be reported else-
where; manuscript in preparation.
3 Cardiff and Oxford sites utilized Lode Excalibur Sport bike, Gronigen,
Netherlands; all other sites utilized a Monarch 874E bike, Monark Exercise AB,
Vansbro, Sweden).
4 Full results from the expired air and blood samples will be reported elsewhere;
manuscript in preparation.
5 Training for the Norway site, which was added mid-way through the trial, was
conducted via remote video-conferencing.2.13. Statistical analysis
Descriptive data includes evaluation of eligibility, recruitment,
retention and adherence rates with 95% conﬁdence intervals. Pre-
dicted VO2maxwas compared to actual VO2max (baseline) on data
from two sites using Pearson correlation coefﬁcients. Graphical il-
lustrations were used to check distributions of outcome data. Pri-
mary and secondary analyses compared outcome measures
between intervention and control groups, using Analysis of
Covariance (ANCOVA) controlling for age, UHDRS TMS, gender and
baseline measure on the outcome of interest. A pre-deﬁned sta-
tistical analysis plan was followed. All analyses were conducted on
an intention-to-treat basis; primary analysis used complete case
data set.2.14. Ethics
The trial was approved by Wales Research Ethics Committee 2
(Wales REC 2; 13/WA/0315).3. Results
3.1. Recruitment and randomization
Three hundred and fourteen adults were assessed for eligibility
over 11 months, and 32 were recruited and randomized (50%, 95%
CI [38.1,61.9]) (see Fig. 1). Recruitment was monitored throughout
the trial; two sites had low recruitment secondary to stafﬁng issues,
so another site was added. Seventeen participants were random-
ized to intervention; eight exercised at home and nine in a hospital/
research laboratory. Twenty-six of the 32 participants were taking
one ormoremedications at the time of baseline assessment. Table 2
provides baseline data and medication use for both groups.3.2. Adverse events (AE)
Two AEs occurred in the intervention group. Symptoms of
concomitant conditions were aggravated during the intervention
(recurrence of back pain in one participant and Wolf Parkinson
White syndrome in another). The participants were subsequently
withdrawn. Two serious adverse events (SAEs) occurred in the
control group. One SAE was attempted suicide, which occurred
within one week after Week 13 Assessment, and was classiﬁed as
possibly related. While it is impossible to make a direct correlation
between the assessment and attempted suicide, the worst-case
classiﬁcation was adopted. The participant was hospitalized and
returned home with community psychiatric team support. The
other SAE was a suicide and classiﬁed as unlikely to be related.63.3. Retention
Three individuals (intervention group) were withdrawn within
the ﬁrst month due to concomitant medical conditions (Fig. 1),
resulting in 14 participants in the intervention and 15 in the control
group for ﬁnal analysis (retention rate of 90.6%, 95% CI [73.4, 97.5].
All assessors remained blinded throughout the study.6 The site PI conﬁrmed that there were no suicidal plans at the time of the
participant’s most recent clinical visit. The SAE occurred 3 months following the
second assessment and 2 months following the last study contact date when the
trainer delivered the control intervention program between Assessment 2 and 3.
Table 2
Baseline Characteristics and Medication use for all participants. Mean (SD) [Range] Scores are reported for age, Total functional capacity, Total Motor score, and Symbol Digit
Modality.
Variable Control group (n ¼ 15) Intervention group (n ¼ 17)
Gender (men:women) 7:8 9:8
Age (y) 51(17) [19e76] 53 (11) [22e69]
Total functional capacity score (TFC) 9 (3) [3e13] 8 (3) [2e13]
UHDRS Total Motor Score (TMS) 32 (14) [12e54] 39 (22) [4e85]
UHDRS Symbol Digit Modality Test
Cognitive assessment (SDMT)
28 (10) [14e45] 23 (9) [6e44]
Medications Antichoreic (n ¼ 4)
Antidepressant (n ¼ 8)
Antihypertensive (n ¼ 1)
Analgesic (n ¼ 4)
Other (n ¼ 8)
Antichoreic (n ¼ 4) Antidepressant (n ¼ 11)
Antihypertensive (n ¼ 4)
Analgesic (n ¼ 0)
Other (n ¼ 8)
Medication changes n ¼ 3
Addition of anti-choreic (n ¼ 1); Addition of diabetes management
medication (n ¼ 1); Course of antibiotics (n ¼ 1)
n ¼ 2
Increase in anti-hypertensive (n ¼ 1); Decrease
in anti-depressant (n ¼ 1)
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Thirteen of the 14 participants who completed the trial
completed >75% of the required sessions (92.9%, 95% CI
[64.2,99.6]); one participant completed 61% of sessions secondary
to illness. For the aerobic exercise,10/13 achieved average target HR
within aerobic zone (65e85% APMHR) for at least 75% of the ses-
sions; 3/13 were able to achieve HR at 60% APMHR. UHDRS TFC
scores for these participants were 2, 6, and 7 and UHDRS TMS were
85, 65 and 66 respectively, indicative of middle-late stages of the
disease.3.5. Falls
Twenty-one out of 32 participants completed the health and
falls diaries. Mean (median) number of falls in control group was
1.12(1) (n ¼ 8; 1 excluded) and 0.83(0) (n ¼ 12) in intervention
group. Diaries for one participant were excluded due to inaccurate
completion.3.6. Outcomes
Predicted VO2 max for each participant at two sites was
compared to actual VO2 max obtained from expired air (r ¼ 0.88,
n ¼ 157).
The intervention group had better ﬁtness as measured by pre-
dicted VO2 max (Table 3) (difference: 492.3 ml min1, 95% CI:
[97.1,887.6]). There was also improvement on UHDRS mMS (inter-
vention arm 2.9 points lower, 95% [5.42, 0.32]). Weight was
different between groups at follow up (intervention arm 2.25 kg
lighter 95% CI: [4.47, 0.03]). There were no differences between
groups on other outcome measures.
At Week 26 phone call, nine control participants and nine
intervention participants provided EQ-5D scores. EQ-5D mean (SD)
scores in control and intervention arms were 0.78(0.14) and
0.80(0.21) respectively. Eight control participants and nine inter-
vention participants provided IPAQ scores. Mean (SD) IPAQ scores
in control and intervention arms were 1753(1802) and 988(890)
respectively.7 Data from 2 participants at the Cardiff site is missing from this analysis; one due
to difﬁculty with a participant using the equipment, one secondary to equipment
malfunction.4. Discussion
Here we report data from a short-term, multi-modal exercise
program in people with HD with tapered support. The intervention
was safe and feasible, and evaluation of exploratory outcomes
revealed signiﬁcant improvements in ﬁtness and motor function.
We demonstrated that people with HD could exercise safely in an
aerobic zone and conduct progressive strengthening exercises,
despite the presence of sometimes advanced motor impairments.
Importantly, individuals in the intervention group did not have a
greater incidence of falls or AEs compared to control participants.
Individuals in the intervention group demonstrated lower
weight at Week 13 compared to control group.While in the general
population weight loss after exercise is generally considered a
positive outcome, in this population it is not necessarily desirable.
Weight loss is common in HD and has been shown to be correlated
with CAG repeat [17]. Previous studies in animal models of HD have
also shown a propensity towards weight loss following exercise [2].
The role of nutrition to supplement potential weight loss from
increased physical activity will be an important component of
future trials and should likely include analysis of body composition.
This study initially aimed to recruit 42 participants, which was
not achievedwithin a 10month time period; this was primarily due
to site stafﬁng issues. In addition, we had a large number of par-
ticipants who did not meet inclusion/exclusion criteria. While
many of these individuals had psychiatric or behavioural problems,
these criteria conceivably excluded potential participants who may
beneﬁt most from exercise, such as those with anxiety or depres-
sion. Despite this, our study included individuals with a wide range
of motor and functional capacity.
Physical limitations and inability to use the exercise bike were
also primary reasons for exclusion; this was likely representative of
individuals in the mid-late stages of the disease, who may be more
appropriate for other types of rehabilitation intervention (e.g. task
speciﬁc training [18]). In addition approximately 20% of partici-
pants lived too far away to participate, either for the participant or
trainer to travel for training sessions. As HD is a relatively rare
disease, future studies should include strategies to promote remote
training and monitoring, or local professionals to support exercise
programs.
This intervention incorporated a tapered support program,
providing 1:1 instruction for the ﬁrst weeks that decreased over 12
weeks. Trainers served two important purposes: to monitor that
the program was being conducted as intended, and to provide
support and encouragement to facilitate adherence. The support
structure appears to have been effective, in that 13/14 participants
adhered to the program, with only one participant having lower
Table 3
Unadjusted Descriptive Statistics Split by Group for all Outcome Measures at baseline and 13 weeks, along with adjusted treatment effect estimates from a complete case
ANCOVA Analysis.
Construct Outcome measure Baseline Week 13 Adjusted estimate of visit 2 and effect
sizes from ANCOVAa
p-
value
Control Intervention Control Intervention
Mean (SD) n Mean (SD) n Mean (SD) n Mean (SD) n Treatment effect estimate
(95% CI)
Effect
size
Fitness Predicted VO2 Max (ml.min-1) 1767.39
(755.28)
15 1585
(546.14)
17 1812.49
(672.5)
13 2045.77
(687.66)
14 492.32 (97.08, 887.56) 0.73 0.02
Motor
function
UHDRS modiﬁed Motor Score (mMS)
[21]
15 (7) 15 18 (7) 17 14 (7) 15 16 (7) 14 2.87 (5.42, 0.32) 0.43 0.03
15 rep chair stand time (sec)a [22] 47.1 (19.9) 15 47 (26.6) 17 42.3 (17.3) 15 47.6 (21.4) 14 5.57 (23.99, 17.32) N/A 0.59
Three minute walk (m) [23] 213.7 (72.6) 15 225.8 (73.8) 17 220.1 (71.1) 15 218.5 (50.9) 14 4.68 (20.38, 29.74) 0.08 0.70
Finger Tapping score (no.taps in 10 s)a
[24]
33.6 (12.4) 15 27.5 (13.1) 16 34.4 (13.4) 15 30 (11.3) 14 12.69 (9.22, 39.88) N/A 0.26
Physical
Activity
IPAQ MET-Minutes [25] 1335.2
(1002.7)
15 1249.7
(1054.4)
17 1347.7
(1839.7)
15 3104.4
(3836.7)
14 1288.67 (459.05, 3036.4) 0.42 0.14
Dual-tasking Simple dual task walk time (sec) [26] 14.04 (7.02) 15 12.85 (4.11) 17 13.08 (6.38) 15 12.54 (3.61) 14 0.29 (2.79, 3.37) 0.06 0.85
Complex dual task walk time (sec)
[26]
22.93 (19.5) 15 16.41 (4.99) 17 17.84
(10.06)
15 15.48 (5.03) 14 1.42 (2.71, 5.56) 0.18 0.48
Cognition Symbol Digit Modalities Test (no.
correct) [27]
28 (10) 15 23 (9) 17 29 (9) 15 23 (12) 14 0.09 (3.04, 3.22) 0.01 0.95
Category Verbal Fluency (no. correct)
[12]
17 (5) 15 13 (6) 17 17 (5) 15 12 (5) 14 1.13 (4.83, 2.57) 0.2 0.53
Stroop colour naming (no. correct)
[12]
47 (12) 15 41 (16) 17 48 (13) 15 39 (14) 14 4.27 (10.16, 1.63) 0.31 0.15
Word reading (no correct) [12] 64 (15) 15 57 (21) 17 65 (22) 15 53 (19) 14 5.39 (17.55, 6.76) 0.26 0.36
Interference (no correct) [12] 27 (8) 15 23 (9) 17 27 (9) 15 23 (9) 14 0.71 (3.79, 5.21) 0.08 0.74
Trailmaking A time (sec)a [27] 54.9 (22.3) 15 82.1 (59.2) 17 51.7 (18.7) 15 91.6 (61.7) 14 8.54 (12.39, 34.45) N/A 0.43
Trailmaking B time (sec) [27] 133 (69) 15 153.1 (65.7) 15 145.2 (71.9) 15 171.5 (79.4) 14 1.76 (40.86, 37.33) 0.02 0.92
Depression Hospital Anxiety and Depression
Scalea [28]
11 (9) 15 9 (9) 17 11 (9) 15 7 (6) 14 20.61 (59.55, 54.9) N/A 0.50
Global
Health
EQ-5D-3L [29] 0.74 (0.17) 15 0.77 (0.19) 17 0.75 (0.19) 15 0.81 (14) 14 0.055 (0.097, 0.207) 0.34 0.42
Weight Weight (kg) 76.5 (18.3) 15 79.9 (16.5) 17 77.2 (18.3) 15 80 (16.3) 14 2.25 (4.47, 0.03) 0.13 0.047
a Log transformed hence % difference between arms (with 95% CI) rather than adjusted treatment effect.
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Week 26 suggested that while general health outcome remained
relatively unchanged, participants in the intervention group
appeared to return to low levels of physical activity after the sup-
port structure was removed.
Three participants in this study were unable to consistently
achieve 65% APMHR while exercising on the bike. This was likely
due to motor and coordination impairments, which may make it
difﬁcult for people with HD to maintain the speed necessary to
achieve a higher HR. Despite this, an overall effect of improving
ﬁtness was seen, which indicates that in this population 60%
APMHRmay be adequate to achieve a training effect (e.g. change in
VO2 max).
Positive results in terms of safety, feasibility and outcomes
suggest that a larger scale, conﬁrmatory trial of exercise interven-
tion in people with HD is now warranted. This study has indicated
that predicted VO2 max is sensitive to change in this population,
and thus demonstrates the construct validity of VO2 max as an
outcome measure for an exercise intervention in this population.
For future studies, based on the observed effect size in predicted
VO2 max of 0.73 we would require 41 participants per group (for
analysis) in order to have 90% power to identify this effect as sta-
tistically signiﬁcant at the 5% level using a twoesided comparison
of means.4.1. Limitations and future directions
As a feasibility study, and one of the ﬁrst to systematically
evaluate a multi-modal exercise intervention in HD, we considered
it important to not add complexity through the introduction of an
active comparator, which should be included in future studies.These may include interventions that focus on physical activity
education as well as different modes and intensities of exercise.
Future studies should also consider additional measures of func-
tional abilities, disease-speciﬁc quality of life and measures of
muscle strength.
While this study demonstrated changes in ﬁtness and motor
function, there was not carry over to walking ability or sit to stand,
or to cognitive function. Extending the intervention to longer du-
rations may be important to evaluate the potential for exercise to
have effects on cognition and other functional abilities [19,20].
Furthermore, exercise may be most feasible and have the potential
for disease modiﬁcation for individuals in the pre-manifest or
prodromal stages of HD, and consideration of early intervention is
necessary. Finally, studies are needed to fully understand the
mechanistic underpinnings by which exercise can exert its effects
across all stages of the disease.
The ﬁndings in this study are generalizable to a relatively limited
number of individuals with HD, who are mobile and have limited
behavioural or psychiatric issues. We recognize that our exclusion
criteria potentially limited a large number of individuals with HD
who may have most beneﬁted from the intervention, however we
believed it important to set these criteria as a minimum require-
ment for ethical and scientiﬁc reasons and to establish feasibility in
a subgroupmost likely to complete and potentially beneﬁt from the
intervention.Funding
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